JAN 12, 2021 10:58 AM PST

SGLT2 Inhibitors Can Reduce the Cardiovascular Risk for Diabetics Being Treated with Insulin

WRITTEN BY: Jasper Cantrell

One of the biggest problems that come alongside diabetes is the increased risk of cardiovascular disease. Treatment of diabetes often reduces the risk, but some scientists wonder if the treatments reduce the risk by treating diabetes or directly affecting the cardiovascular system.

One of the go-to treatments for type 2 diabetes is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. This protein is a regulator of sugar in the blood, and its inhibition can increase the amount of sugar excreted by the bladder. Dapagliflozin, empagliflozin, and canagliflozin are all drugs that use this mechanism to control sugar levels in diabetic patients. Still, some recent evidence suggests these may also independently reduce the risk of cardiovascular disease.

In a new study, a team from the University Medical Center Hamburg-Eppendorf in Germany wanted to investigate further. A few recent studies have shown that SGLT2 inhibitors lowered the risk of cardiovascular hospitalization or death in patients with diabetes. However, these studies were conducted in the absence of insulin, a common diabetes treatment. This new study investigated whether the reduced cardiovascular risk could also be seen in patients treated with insulin.

To do this, the team examined the cardiovascular biomarkers hematocrit, red blood cell count, and reticulocyte in a double-blind, randomized trial. All are indicators of cardiovascular risk. Enrolled patients were being treated with insulin and were put in either a placebo group or given a certain dose of the SGLT2 inhibitor dapagliflozin.

The study found that dapagliflozin treatment increased both hematocrit levels in the blood and red blood cell count across the 104-week trial. Reticulocytes, a precursor to red blood cells, increased during the first 4-weeks but then dropped back down to levels akin to the placebo group. These results suggest that SGLT2 inhibitors have the same effect against cardiovascular risk in diabetic patients treated with insulin as they do with patients not being treated with insulin.

This study followed markers of cardiovascular risk during dapagliflozin treatment in a group of diabetic patients already being treated with insulin. They did not independently measure the onset of cardiovascular disease in their study, however previous studies had found that the increases to hematocrit, red blood cell count, and reticulocytes correlate well with a reduced cardiovascular risk in diabetic patients.  

The study concludes, “In summary, we show that dapagliflozin induces a long-term and dose-dependent elevation in haematocrit that is preserved in patients receiving concomitant insulin treatment, including chronic insulin therapy.”

Sources: Nature Scientific Reports, AJMCtv

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 22, 2020
Cardiology
Can Playing Your Favorite Music Improve Your Physical Performance?
AUG 22, 2020
Can Playing Your Favorite Music Improve Your Physical Performance?
If you go to the gym, you will usually see people with headphones jamming out to their favorite music while exercising. ...
SEP 03, 2020
Cardiology
Does Hypertension Make It Harder to Recognize Others Emotions?
SEP 03, 2020
Does Hypertension Make It Harder to Recognize Others Emotions?
Have you ever felt your blood pressure rise when you get angry or stressed? Well, this phenomenon is unique in that it l ...
OCT 21, 2020
Cell & Molecular Biology
Extracellular Vesicles Help Heart Cells Survive a Heart Attack
OCT 21, 2020
Extracellular Vesicles Help Heart Cells Survive a Heart Attack
During a heart attack, blood flow is blocked and cells lose oxygen and begin to die. Scientists are developing many new ...
NOV 05, 2020
Cardiology
Investigating Platelet-Derived Extracellular Vesicles in Blood Clotting
NOV 05, 2020
Investigating Platelet-Derived Extracellular Vesicles in Blood Clotting
In our bodies, there are millions of signals and packages being sent and received every second. In the past several deca ...
NOV 14, 2020
Cardiology
Chili Peppers May Help Us Live Longer
NOV 14, 2020
Chili Peppers May Help Us Live Longer
Researchers presented preliminary data at the American Heart Association's Scientific Sessions 2020 that suggested t ...
DEC 17, 2020
Cardiology
A Heart Attack Induces Change in Cytokine Signaling in Patients
DEC 17, 2020
A Heart Attack Induces Change in Cytokine Signaling in Patients
Cellular signaling is critical for the body to coordinate everything from heart rate to not hitting yourself when you mo ...
Loading Comments...